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The aim of this study was to assess the hepatotoxicity cases described in the literature, attributed to the 
consumption of Herbalife® products, and to determine whether a causal relationship exists between the 
reported cases of liver injury and the use of these products. A literature search was performed on the 
PubMed, LILACS and PAHO databases. Seven publications reporting a total of 53 cases of hepatotoxicity 
linked to the use of Herbalife® products were retrieved. All of the studies lacked sufficient information to 
some degree, whether related to patients’ history, concomitant use of medication and/or other compounds 
(including alcohol), observations on interrupted use (dechallenge), results found with markers, viral 
serology and autoantibodies or observations concerning re-exposure to the products. In addition to these 
items, the lack of clear information on the type of products evaluated and their respective composition is an 
important factor to be considered. Furthermore, data quality was also questionable due to the presence of 
confounding factors, absence of proper exclusion of alternative explanations, and the use of questionable 
methods for attributing causality. Hence, an association between hepatotoxicity and consumption of these 
products cannot be proven based on the data collected and rigorous scientific analysis. 
Uniterms: Hepatotoxicity. Herbalife®. Herbalife products®/consumption/hepatotoxicity. Dietary 
supplements. Causality assessment.
Este estudo teve como objetivo avaliar os casos de hepatotoxicidade descritos em literatura, atribuídos ao 
consumo de produtos Herbalife®, e verificar se é possível ou não estabelecer uma relação de causalidade 
entre eles. Realizou-se levantamento bibliográfico nas bases de dados PubMed, LILACS e PAHO e foram 
encontrados 7 manuscritos reportando 53 casos de hepatotoxicidade, relacionados ao uso de produtos 
Herbalife. Observou-se que todos trazem, de alguma forma, quantidade insuficiente de informações 
em relação ao histórico dos pacientes, ao uso concomitante de medicamentos e/ou outros compostos 
(incluindo álcool), às observações após a interrupção do uso (dechallenge), aos resultados referentes 
a marcadores e sorologia virais e autoanticorpos e às observações quanto à reexposição aos produtos. 
Some-se a estes fatos a falta de identificação clara e comprovada do tipo de produto envolvido, assim 
como sua composição. Além disso, a qualidade dos dados também é questionável devido à presença 
de variáveis de confundimento, ausência de exclusão adequada de explicações alternativas e ao uso de 
métodos discutíveis de atribuição de causalidade. Desta forma, a associação entre hepatotoxicidade e 
o consumo destes produtos não pode ser comprovada, após observar o conjunto dos dados coletados, 
utilizando-se rigor técnico-cientifico.
Unitermos: Hepatotoxicidade. Herbalife®. Produtos Herbalife®/consumo/hepatotoxidade. Suplementos 
alimentares. Avaliação de causalidade.
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INTRODUCTION
Currently, there is a growing number of products 
with potential health benefits for consumers available on 
the food market, including foods, fortified foods (with 
minerals, vitamins or botanical extracts) and dietary 
supplements (ILSI, 2003; Schilter et al., 2003; Coppens 
et al., 2006; Kroes, Walker, 2004). Excessive exposure to 
dietary supplements and limited information available on 
the toxicity of some food ingredients have raised major 
concerns amongst scientific and regulatory communities 
over their safety (ILSI, 2003; Abdel-Rahman et al, 2011; 
Speijers et al., 2010; Van Breeman, Fong, Farnsworth, 
2008; Kroes, Walker, 2004; Seef, 2009; Bunchorntavakul, 
Reddy, 2013; Stickel et al., 2011). 
Against this background, there have been reports of 
adverse effects on human health related to the consumption 
of dietary supplements. The assessment of publications 
linking supplement consumption to acute and chronic liver 
injuries has indicated that these reports are mainly related 
to the consumption of products involving botanical or 
botanical preparations. However, the proportion of herbal-
induced liver injury relative to the overall frequency of 
all hepatotoxicity cases is not well defined (Seef, 2009).
The aim of this article was to assess the hepatotoxicity 
cases described in the literature, attributed to the 
consumption of Herbalife® products, and to determine 
whether a causal relationship between the reported cases 
of liver injury and the use of Herbalife® products can be 
established or otherwise. 
METHODS
A literature search was performed on the PubMed, 
LILACS and PAHO databases in order to identify scientific 
publications involving case reports of hepatotoxicity and 
use of Herbalife® products. The following key words 
were used: Herbalife, Herbalife products and Herbalife 
hepatotoxicity, for the period spanning from January 2000 
to February 2015. 
RESULTS
Thirty-two publications were found, seven of 
which described case reports linking hepatotoxicity to the 
consumption of these products. These seven publications 
reported 53 cases of hepatotoxicity, which are summarised 
below in order of publication. 
Elinav et al. (2007) described twelve patients who 
suffered unexplained acute hepatitis during the 2002-
2004 period in Israel. These patients had consumed 
various Herbalife® products prior to the onset of clinical 
symptoms. The twelve patients (11 women and 1 man) 
answered a detailed questionnaire and all medical records 
were collected, investigated and reviewed. Hepatocellular 
injury was reported in 11 cases, and mixed liver injury 
in 1 case (hepatocellular and cholestatic). Some patients 
were using other medications concomitant to the 
Herbalife® products and had a history of previous illness. 
In the causality assessment, carried out according to the 
World Health Organization (WHO) criteria for Causality 
Assessment of Suspected Adverse Reactions, 3 cases were 
classified as certain, 6 as probable and 3 as possible. It was 
noted that these entailed a list of products consumed by 
the patients, numbering at least 6 and up to 17 products 
per person. All patients stopped using the products after 
being diagnosed with hepatitis. Four patients were treated 
with corticosteroids, a further four with ursodeoxycholic 
acid and three (presenting with fulminant or sub-fulminant 
hepatic failure) with intravenous N-acetylcysteine. 
The hepatitis diagnosed was completely resolved in 11 
patients. One patient with positive hepatitis B surface 
antigen (HBsAg+) and IgM anti-HBc antibodies (against 
the hepatitis B core antigen) developed fulminant liver 
failure, underwent urgent liver transplantation, but died 
due to complications resulting from the transplant. A 
2-year follow up revealed no long-term complications in 
any of those patients who did not resume consumption of 
the products. Three patients that resumed consumption of 
Herbalife® products (based on personal decision, without 
informing their doctors) after normalization of liver 
enzymes, had a second episode of liver injury.
Although the authors stated that the analysis of 
these 12 patients suggested a causal association between 
consumption of Herbalife® products and development of 
acute liver injury, they also pointed out that patients with 
underlying liver disorders may be more susceptible to liver 
injury induced by the consumption of these products. Other 
risk factors for predisposition, which were not identified, 
may include genetic susceptibility, such as P450 enzyme 
polymorphism and individual aberrations in immune 
response. The authors also mentioned the fact that the 
exact mechanism for liver injury in their patients was not 
established; furthermore, the plasma-cell rich infiltrates 
identified in four biopsies and occasional transient 
presence of autoantibodies suggested the possibility of 
immune-mediated liver toxicity. The authors further 
maintained that, despite the supposed association between 
the consumption of Herbalife® products and the hepatic 
toxicity observed, it was not possible to conclude at this 
juncture whether the consumption of these products posed 
a major health threat for the general population. Toxicity 
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occurred in a minority of consumers, and the authors 
suggest that this may have resulted from a hepatotoxic 
ingredient, excessive consumption of a safe ingredient or 
contamination during product processing, in combination 
with individual predisposition (Elinav et al., 2007).
Schoepfer et al. (2007) described 10 cases of 
hepatotoxicity potentially involving Herbalife® products 
in Switzerland. These cases occurred between 1998 
and 2004, and were identified through a questionnaire 
sent to the departments of medicine of public hospitals, 
gastroenterology/hepatology and pathology divisions, and 
via the Swiss pharmacovigilance database. The population 
studied included 6 women and 4 men, aged between 30 
and 69 years (median age of 51), with absence of co-
morbidity and pre-existing illness, except for one patient 
who presented serological evidence of past hepatitis A and 
B, one who had evidence of previous hepatitis E, and one 
patient who reported consumption of 50 g of alcohol/day. 
In most cases (n=9), hepatocellular injury was reported, 
and mixed liver injury (hepatocellular/cholestatic) was 
observed in only one case. Causality assessment was 
carried out according to the World Health Organization 
(WHO) criteria for Causality Assessment of Suspected 
Adverse Reactions and revealed 2 cases as certain, 7 
as probable and 1 as possible. It is worth mentioning 
that all of the patients consumed at least three and up to 
twelve different Herbalife® products at the same time, 
complicating the search for a specific hepatotoxin. For two 
of the patients, it was not known which specific products 
had been consumed.
According to the authors, all the patients were alive 
when the publication was completed, but one of these 
needed a liver transplant. One patient was presumed 
to have continued consuming Herbalife® products, but 
remained asymptomatic at the time of completion of the 
article, despite being diagnosed with cirrhosis.
The  au thors  cons idered  tha t  the  cases  of 
hepatotoxicity related to the consumption of these 
products represented a low incidence in the context of their 
wide use, but did not rule out a possible cause for concern 
and warned about the risk of using several Herbalife® 
product in association. Furthermore, the authors alerted to 
the fact that the intake of these products is underreported 
by patients who believe that this type of product is not 
harmful to their health, rendering causality assessment 
even more difficult (Schoepfer et al., 2007). 
Chao et al. (2008) described one case of a probable 
diagnosis of toxic hepatitis secondary to the consumption 
of Herbalife® nutritional supplements, reported in 
Argentina. This case involved a 63-year-old woman who 
presented acute cholestatic hepatitis. She reported taking 
three types of Herbalife® products and no medication. 
The result of the viral serology for hepatitis was negative. 
According to the causality assessment, performed using 
the WHO method, this case of hepatitis was classified 
as probable, secondary to the ingestion of Herbalife® 
products.
After having discontinued consumption of these 
products, her hepatic enzyme levels returned to normal 
within 21 weeks. Clinically speaking, the patient improved 
rapidly, with disappearance of pruritus within 4 days after 
discontinuing the reported food supplements. 
The authors concluded that, at present, it is not 
possible to define the liver injury mechanism in patients 
who have consumed Herbalife® products. Suggestions 
ranged from autoimmune mechanisms to a possible 
obstruction in liver outflow. It has also been suggested 
that the presence of a previous chronic hepatic disease 
may increase the likelihood of potential liver injury as a 
result of these products. They also stressed the importance 
of health professionals being aware that not all of these 
products (plant-based food supplements) are safe, that 
cases of severe hepatotoxicity after their consumption 
have been reported, and that diagnosis and causality 
assessment in these cases are extremely difficult (Chao 
et al., 2008).
Stickel et al. (2009) described two cases of liver 
injury potentially related to the use of Herbalife® 
products reported in Switzerland. Causality was 
assessed according to the Council for International 
Organizations of Medical Sciences (CIOMS) scale 
criteria. Toxicological assessments, immunological 
sensitivity tests, microbiological contamination tests 
and experiments with cell cultures were carried out. No 
significant contamination with heavy metals, pesticides, 
antibiotics, alkyl phosphates or softeners were identified 
in the toxicological assessment of one of the products 
(Shake F1). No immunoallergic activation was detected 
on the dermal hypersensitivity tests or the lymphocyte 
stimulation test.
Both patients, a man (78 years old) and a woman 
(50 years old), presented with cholestatic hepatitis and 
high levels of hepatic enzymes. The man reported the 
consumption of alcohol as well as prescription medication 
while medical exams revealed an underlying disease. 
He reported using only one Herbalife® product (shake, 
two different flavours). The woman reported using seven 
Herbalife® products. Causality was assessed according to 
CIOMS assessment criteria and scored as ‘‘probable” in 
both cases. 
The male patient stopped consuming the products 
and continued with routine medication, presenting an 
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immediate improvement in hepatic enzyme levels and 
liver function, with no specific treatment. However, 
8 weeks later the patient again presented high serum 
levels of hepatic enzymes and deteriorated hepatic 
functioning, with coagulopathy and hypoalbuminemia. 
Treatment was started with corticosteroids (40 mg/day) 
and ursodeoxycholic acid (15 mg/kg b.w.) resulting 
in rapid normalisation of the altered values, including 
the coagulation and albumin parameters. Use of the 
two medications was suspended three months after 
normalisation, and no recurrence was reported after 10 
months’ monitoring. In the second episode of hepatitis, 
a transjugular hepatic biopsy was performed and the 
histology showed lobular and portal/periportal hepatitis, 
with no eosinophilia or plasma cells, accentuated 
cholestasis and partial cirrhotic transformation compatible 
with liver injury due to toxicity. The female patient was 
strongly advised to discontinue all food supplements 
and was prescribed ursodeoxycholic acid at 15 mg/kg 
b.w. After 6 months without consuming these products, 
the clinical symptoms stabilised and normalisation of 
AST/ALT levels was recorded, with a sharp reduction in 
cholestatic bio-markers.
The authors stated that these two cases of liver 
injury related to the consumption of Herbalife® products 
added to the growing body of scientific evidence that 
food supplements are a rare but worrying cause of severe 
adverse hepatic reactions, considering that the use of 
plant-based supplements without the recommendation 
of a health professional (in some cases, concomitantly 
with medication) has become more prevalent amongst 
consumer populations. The authors also warned of the 
need for regulatory measures applying stricter control over 
food supplements, and of the need to increase awareness 
amongst consumers and health professionals regarding 
the potential for health damage caused by the use of food 
supplements (Stickel et al., 2009).
Chen et al. (2010) described three cases of liver 
injury induced by weight-loss herbal supplements reported 
in the United States of America, with two cases involving 
Herbalife® products. A standardized causality assessment 
was not reported. In both cases involving Herbalife® 
products, the patients were women, aged 37 and 53 years 
old, who presented with elevated liver enzyme levels and 
reported taking several Herbalife® products. A liver biopsy 
of one of the patients revealed acute necrotizing hepatitis, 
while the initial laboratory values of the other patient 
revealed a hepatocellular pattern of injury, with the liver 
biopsy showing cholestasis.
One of the patients received supportive treatment 
with fluids and nutrition. Her liver enzyme levels declined 
steadily from the day of admission to the eighth day of the 
hospital stay (day of discharge). She was monitored for 
several months and her symptoms continued to improve. 
After two months, the patient’s icterus and jaundice had 
resolved completely. The other patient presented a history 
of painless jaundice and pruritus, but two months after 
complete abstinence from Herbalife® supplements, her 
jaundice resolved and liver tests normalized.
The authors concluded that it was difficult to identify 
the exact ingredient or mechanism which caused liver 
injury because both patients took several Herbalife® 
products. Nevertheless, they stated that the fact there has 
been multiple reported cases in the medical literature 
of hepatotoxicity associated with weight-loss herbal 
supplements (including Herbalife® products) cannot be 
overlooked, although significant liver injury induced by 
herbal supplements taken for weight loss purposes is a 
rare event. They also stressed that consideration should 
be given to the impact of the use of these products on 
patients with underlying chronic liver disease, since these 
products may cause worsening in their synthetic function 
and even fulminant liver failure. The authors therefore 
consider that closer monitoring of patients taking weight 
loss herbal supplements is needed, as is stricter regulation 
by government drug agencies (Chen et al., 2010).
Jóhannsson, Ormarsdóttir and Olafsson (2010) 
described five cases of liver injury potentially related 
to the consumption of Herbalife® products in Iceland 
during the period from 1999 to 2008. Since the original 
publication was published in Icelandic, we had access only 
to the abstract available in English, so the data could not 
be properly assessed. These cases involved 4 women and 
1 man, aged 29 to 78 years (median age of 46); 4 patients 
presented with a hepatocellular and one with a cholestatic 
reaction. The abstract did not detail the types and number 
of Herbalife® products used by the patients, but it was 
stated that they had been used for 1 to 7 months prior 
to presentation. According to the causality assessment 
(WHO method), the cases were classified as certain (n=1), 
probable (n=2) and possible (n=2) regarding their causal 
association to Herbalife® product consumption. 
Since we did not have access to the whole 
publication, we do not have full information on the 
authors’ conclusions. They stated that the hepatotoxicity 
observed in these cases was probably associated with the 
use of Herbalife® products and that hepatotoxicity due to 
herbal drugs and supplements is an important differential 
diagnosis in the investigation of liver injury (Jóhannsson, 
Ormarsdóttir, Olafsson, 2010).
Manso et al. (2011) described 20 cases of liver injury 
associated with the use of Herbalife® products in Spain. 
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These cases occurred from 2003 to 2010 and were drawn 
from the Spanish Pharmacovigilance Centre database. The 
search resulted in 20 reports of liver damage, comprising 
16 female and 4 male patients, aged from 36 to 63 years 
(mean age of 49 years) who presented high levels of 
bilirubin and liver enzymes (ALT, AST and AP). Of the 
20 patients, 14 presented negative viral serology and 2 had 
positive autoantibodies. Fourteen patients were diagnosed 
with hepatocellular lesion, and cholestatic lesion was 
reported in two cases. Causality was assessed using the 
modified Karch and Lasagna algorithm, which ascribes 
levels of probability of association between drugs and 
adverse reactions into the following categories: definite 
> probable > possible > conditional > unlikely. The cases 
analysed were classified as follows: definite – 1; probable 
– 14; and possible – 5. In the majority of cases, several 
Herbalife® products were taken concomitantly, however 
this information was not collected for eight of the patients 
analysed.
The authors stated that these results support a link 
between the consumption of Herbalife® products and 
hepatotoxicity, since there was a clear temporal relation 
between liver injury and consumption of these products 
in all cases, and in most, clinical symptoms and liver 
parameters improved after withdrawal of Herbalife® 
product. The authors also pointed out that, although the 
component(s) responsible for the liver damage is (are) 
unknown, there is concern regarding adverse effects to 
the liver when these dietary supplements are used (Manso 
et al., 2011).
Besides these publications, 10 rebuttals from 
Herbalife® have been published to date in response 
to the various publications which implicate its brand 
(Appelhans et al., 2011; Appelhans, Frankos, Shao, 2012; 
Appelhans, Najeeullah, Frankos, 2013a; 2013b; 2014a; 
2014b; Appelhans, Goldstein, 2011; Appelhans, Frankos, 
2012; Bejar, et al., 2011; Ignarro, Heber, Henig, 2008). In 
summary, these rebuttals express Herbalife’s objection to 
various methodologies which are inappropriately applied 
and subsequently produced inaccurate conclusions in 
regard to the review of cases which involve Herbalife’s 
consumers. Herbalife has stated that the company produces 
hundreds of different products worldwide which also can 
also vary in formulation amongst the 93 markets where 
the products are distributed. Herbalife’s main product 
categories include protein shakes, protein snacks, vitamins 
and nutritional supplements, energy and fitness drinks, and 
skin and hair care products. Herbalife also asserts that no 
single product or ingredient has been common to all the 
cases published to date. The company further states that 
it is unprecedented to publish scientific research without 
citing specific products or ingredients let alone being able 
to apply causality assessment criteria. That said, Herbalife 
has also acknowledged emerging research conducted 
by independent third party experts who have recently 
revisited the historical cases involving Herbalife and are 
also questioning the methodology by which these cases 
were evaluated (Teschke et al., 2013c). In many instances, 
these same experts are assigning weaker causality 
outcomes than were previously determined and certain 
events also appear to have been more likely associated 
with pre-existing etiologies amongst these consumers (e.g. 
viral hepatitis and alcoholism) (Teschke et al., 2013b). It 
can be further assumed that these potential differentials 
may also explain the variety of clinical presentations 
amongst Herbalife patients described in the literature to 
date. 
The most recent publication found was an update on 
hepatotoxicity of herbal and dietary supplements (HDS). 
This review provided an update summary on the topic to 
emphasize the possibility of HDS as a potential cause of 
liver injury. The authors included a topic about Herbalife, 
summarizing all cases described in the literature and some 
possible explanations for them, including spoiled products, 
which may have been contaminated with certain germs or 
chemicals and could have been responsible for local series 
of cases of hepatotoxicity and batch-to-batch variation. 
They also mentioned that no further cases have been 
observed after the latest series from Spain in 2011(Stickel, 
Shouval, 2015).
DISCUSSION
After analysing these publications in which 
hepatotoxicity was attributed to the use of Herbalife® 
products, it was observed that all of them, to some degree, 
lacked sufficient information related to: patients’ history, 
concomitant use of medication and/or other compounds 
(including alcohol), observations on discontinuation 
of use (dechallenge), results found with markers, viral 
serology and autoantibodies, observations concerning 
re-exposure to the products, and specifications of product 
use. Furthermore, data quality is also questionable due to 
the presence of confounding factors, absence of proper 
exclusion of alternative explanations, and the use of 
questionable methods for attributing causality.
Firstly, it should be noted that in most of the 
publications, the Herbalife® brand was considered as a 
whole, without prior analysis of the types of products 
involved or their composition. Secondly, in some cases 
the products were assessed together with plant-based 
products, as if all the products contained botanical 
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components in their composition, which is not the case. 
Several products by the Herbalife® brand do not contain 
extracts of plants or plant parts in their composition. This 
important point was not mentioned by any of the authors 
who claimed a causal association between the Company’s 
products and hepatotoxicity. 
In this context, the attribution of causality loses merit 
when no specific product or chemical substance (or class 
of chemical substances) is indicated as causing the injury. 
In products containing a number of different components, 
including various ingredients routinely used in the food 
industry, as is the case for these products, this question is 
particularly important. Furthermore, the products cited 
were frequently compared to plants and/or plant-based 
products which were not processed industrially during 
manufacture. Good manufacturing practices invariably 
ensure the quality of the final product, plant-based or 
otherwise.
Another important point is that, in many cases, 
the combined use of various Herbalife® products was 
observed, in addition to synthetic and/or plant-based 
medications, rendering it more difficult to establish a 
causal agent and define a mode of action for hepatotoxicity. 
Excessive consumption of various products may also led 
to hepatic overload, potentially important in itself.
For most herbs, herb-induced liver injury (HILI) is 
a rare disease occurring in a few susceptible individuals, 
exhibiting similar characteristics to drug-induced liver 
injury (DILI) and other liver diseases unrelated to herbs 
and drugs. Furthermore, diseases affecting other organs, 
such as the gall bladder, bile ducts and pancreas, may 
mimic the symptoms of HILI and DILI. Isolated clinical 
presentation therefore does not suffice for diagnosing 
HILI, without supplementary information being provided 
and evaluated (Teschke et al., 2012a). 
Hepatotoxicity associated with plant-based products 
is typically established after excluding viral, autoimmune, 
metabolic and anatomical causes of liver test abnormalities. 
Tools (scales and algorithms) are available for assessing 
the causality of liver injury associated with use of drugs 
(Fenkel, Navarro, 2011). Many publications which report 
cases of DILI appear to rely on clinical findings, without 
using any valid criteria for causality assessment (known 
as an ad hoc approach). Publications were identified 
which used the following scales for assessment: the 
CIOMS scale, the Naranjo scale and the WHO global 
introspection method (WHO method). Nevertheless, there 
is no systematic analysis model or scale for causality 
assessment in cases of HILI. Some publications take scales 
originally designed for medications and use them for 
diagnosing HILI cases. The causality assessment methods 
identified in publications involving herb-induced liver 
injury (HILI) included the ad hoc approach, the Naranjo 
scale, the Karch and Lasagna method, the WHO method 
and the CIOMS scale (Teschke, 2013a); the last 3 methods 
were employed in the articles that associated the use of 
Herbalife® products with HILI.
Patients with HILI and DILI in general have a good 
prognosis, but acute liver failure may occur, with a fatal 
outcome or the need for a liver transplant in rare cases. 
As there is no valid specific laboratory marker, diagnosis 
of DILI and HILI requires meticulous clinical assessment 
and the use of an appropriate diagnostic algorithm taking 
into consideration the specific characteristics of the 
hepatotoxicity. 
In case series initially assumed as being DILI, 
alternative diagnoses are common and may have 
accounted for up to 47.1% of such cases in one study 
evaluating the accuracy of hepatic idiosyncratic adverse 
drug reactions initially identified in 138 patients of an 
English health region. In the report, primary underlying 
diagnoses included: bile duct stones, ischemic hepatitis, 
autoimmune hepatitis, sepsis, alcohol-related liver 
disease, Gilbert’s syndrome, hepatitis from infections 
due to cytomegalovirus and Epstein-Barr virus, steatosis, 
postictal state, lymphoma, paracetamol overdose, 
cholangitis, thyrotoxicosis, cirrhosis due to hepatitis C 
and cryptogenic cirrhosis. In 15.2% of the cases, the cause 
was undetermined, whereas reactions were considered to 
be drug related in only 37.7% (Teschke et al., 2013b). The 
same may have occurred for cases in which hepatotoxicity 
was attributed to the consumption of Herbalife® products, 
and therefore such reports need to be analysed more 
carefully and judiciously.
Teschke et al. (2013b) analysed previously published 
cases of HILI to assess the frequency and characteristics 
of alternative causes, unrelated to the use of plant-
based medication and dietary supplements. Among the 
cases assessed were several publications which linked 
hepatotoxicity with the consumption of Herbalife® 
products. Of the 42 cases of herb-induced liver injury 
reported in the publications evaluated, 11 cases had 
alternative causes (Teschke et al., 2013b). Table I shows 
the results expressed in number of cases initially diagnosed 
as HILI, number of cases with alternative causes, the 
causality assessment method used and the alternative 
causes proposed.
Thus, it can be shown that even where literature 
searches have identified various different plant-based 
products, including Herbalife® products, as responsible 
for causing toxic liver diseases, the data in these cases are 
generally confused with other alternative diagnoses. The 
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TABLE I - Frequency of alternative causes proposed for cases initially diagnosed as HILI
Publication Nº of cases initially diagnosed as HILI
Nº of cases with 
alternative causes
Causality assessment 
method Alternative causes
Elinav et al. (2007) 12 4 WHO
Hepatitis B, primary 
biliary cirrhosis, and 
steatosis of the liver.
Schoepfer et al. (2007) 10 2 WHO Hepatitis E and Giant Cell Hepatitis.
Manso et al. (2011) 20 3 Karch and Lasagna
Mallory’s corpuscle 
hepatitis and liver injury 
due to co-medication.
majority of these reports are flawed with respect to product 
quality, data presentation and the causality assessment 
method used (Teschke et al., 2012a). 
Regarding data quality, it is important that the case 
report include sufficient, complete, reliable data, given 
the various confounding factors and absence of specific 
biomarkers for hepatotoxicity, which make HILI difficult to 
diagnose. Depending on the clinical presentation, several 
of these liver diseases may potentially be relevant and must 
be considered. This is a serious problem in retrospective 
analyses based on cases collected from hospitals and 
spontaneous reports by regulatory agencies, which are 
the main sources of data in publications involving cases 
of HILI, including the cases in which Herbalife® products 
are cited. Certain items are important to guarantee the 
validity and credibility of the data collected either from 
case studies or spontaneous reports, namely: competent 
data acquisition and complete documentation, transparent 
data presentation, and assessment of the temporal 
association of the causal relation.
With respect to the quality of the causality assessment 
methods, in cases where hepatotoxicity due to plants and/
or plant-based products is suspected, proper management 
of the causality assessment is essential to guarantee correct 
diagnosis and exclude alternative diseases which may 
require other specific treatment (TESCHKE2013a). Some 
items used to guarantee proper causality assessment in cases 
of HILI include: use of a liver-specific causality assessment 
method, an assessment method validated for hepatotoxicity, 
a structured quantitative method, assessment performed by 
qualified hepatologists with clinical experience, regulatory 
assessment with the assistance of external specialists, and 
a high degree of transparency in the assessment results 
(Teschke et al., 2012a).
 As cited above, the causality assessment methods 
identified in publications involving herb-induced liver 
injury include the ad hoc approach, the Karch and 
Lasagna method, the Naranjo scale, the WHO method 
and the CIOMS scale (Teschke, 2013a), some of which 
were used in publications involving Herbalife® products. 
Teschke (2013a) hold that the most appropriate tool for 
causality assessment in cases of hepatotoxicity is the 
CIOMS scale. The CIOMS scale is specific and validated 
for hepatotoxicity, which is not the case for the Naranjo 
scale, the WHO global introspection method or the ad hoc 
approach. As these approaches are not specific, and not 
validated for causality assessment of hepatotoxicity, the 
authors consider them obsolete. Although documentation 
quality is important in cases of liver injury, it is not always 
possible to obtain complete information to establish 
causality in certain cases. Assessments based on the 
CIOMS method do not reject cases with incomplete data, 
but assess the missing items by subtracting points from the 
score, unlike the WHO method which does not present a 
list of required items, and therefore does not specifically 
consider data quality (Teschke et al., 2012a). Table II 
shows the key items for causality assessment in cases of 
plant-induced liver injury involved in each assessment 
method, demonstrating the superiority of the CIOMS scale 
for assessing these cases.
Another important point in cases where the suspected 
cause of hepatotoxicity is the ingestion of plants or 
plant-based products, is whether the re-exposure test (in 
this case unintentional) was positive, i.e. whether the 
patient suffered alterations in hepatic parameters and/
or recurrence of the symptoms when re-exposed to the 
product (without medical recommendation or controls). 
In the absence of accepted hepatotoxicity biomarkers for 
the majority of liver injuries induced by medication or 
plants and/or plant-based products, a positive response to 
re-exposure is commonly regarded as the gold standard for 
establishing causality in cases of hepatotoxicity, assuming 
that the well-established specific criteria are met (Teschke 
et al., 2013c). 
Teschke et al. (2013c) analysed the validity of the 
re-exposure tests and the causality assessment methods 
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in cases of hepatotoxicity related to the consumption 
of Herbalife® products with positive re-exposure tests. 
Of the 53 cases of suspected hepatotoxicity related to 
the consumption of Herbalife® products found in the 
literature, they selected eight cases with a high degree of 
causality and positive (unintentional) re-exposure tests. 
In all these cases, the reports of positive re-exposure tests 
for hepatotoxicity caused by Herbalife® products led 
initially to a high degree of suspicion that the liver injury 
was caused by consumption of these diet supplements. 
However no specific criteria were applied to assess the 
re-exposure tests. 
When the proposed criteria were used to determine 
whether the re-exposure tests were positive, Teschke et 
al. (2013c) found that not all the re-exposure tests in these 
eight cases could be considered positive. One was proved 
to be positive, another was proved to be negative, while in 
the other six cases, due to absent or insufficient data (ALT 
values), it was not possible to interpret the results (Teschke 
et al., 2013c). Problems with data in re-exposure tests 
are not exclusive to publications involving Herbalife® 
products. Problems of this kind have been reported in 
various publications relating liver injury with medication, 
diet supplements and plant-based products. Analysis of 30 
cases over the last three decades, in which it was asserted 
that the re-exposure test was positive, revealed that in 
many cases there were no detailed descriptions of the re-
exposure test, and no information on the real ALT values, 
precluding any assessment in accordance with the criteria 
established for the re-exposure test to be considered 
positive (Teschke et al., 2013c).
Furthermore, the causality assessment methods 
used in the eight cases re-assessed by these authors were 
not specific for hepatotoxicity, and were considered 
obsolete for this kind of analysis. The authors re-assessed 
the causality in these cases using the CIOMS scale. The 
results are described in Table III and show much lower 
causality levels than those published previously (Teschke 
et al., 2013c).
Taking into account all the factors discussed here 
with respect to the particularities and limitations of 
causality assessment of liver injury induced by plants/
plant-based products, Teschke et al. (2012a) proposed 
a structured method for HILI causality assessment, 
TABLE II - Criteria involved in each causality assessment method (Teschke et al., 2012b)
Qualifying Items CIOMS Scale Naranjo Scale WHO Scale Ad hoc approach
Application 
   Hepatic ADRs 
   Non-hepatic ADRs
 
+ 
-
 
- 
+
 
- 
+
 
- 
+
Specific criteria 
   Structured 
   Quantitative 
   Liver-Specific
 
+ 
+ 
+
 
+ 
+ 
-
 
+ 
- 
-
 
- 
- 
-
Hepatotoxicity-validated + - - -
ADRs: adverse drug reactions.
TABLE III - Comparison of initial causality assessment results with causality assessment results using the CIOMS scale (Teschke 
et al., 2013c)
Patient Publication Initial causality assessment (method)
Causality assessment using 
CIOMS scale
1 Hoffmann et al., 2005 apud Teschke et al., 2013c Highly probable (--) Probable
2 Elinav et al., 2007 Certain (WHO) Improbable
3 Elinav et al., 2007 Certain (WHO) Improbable
4 Elinav et al., 2007 Certain (WHO) Improbable
5 Schoepfer et al., 2007 Certain (WHO) Excluded
6 Jóhannsson, Ormarsdóttir, Olafsson, 2010 Probable (WHO) Excluded
7 Manso et al., 2011 Definite (Karch and Lasagna) Improbable
8 Manso et al., 2011 Probable (Karch and Lasagna) Excluded
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considering the essential information which must be 
present in a case report to allow assessment (Teschke et 
al., 2012a). The essential key elements for proper causality 
assessment included detailed clinical characteristics of the 
patients; complete description of the plant-based products 
and their use; details of clinical course and temporal 
association; values of liver parameters; alternative 
diagnoses; re-exposure and known hepatotoxicity of the 
plant.
The quantity of information which they suggest 
is necessary to establish an adequate causality relation 
demonstrates the complexity of this analysis. It also 
indicates the need to use specific criteria when assessing 
re-exposure tests and upon choosing the most complete 
and specific method of causality assessment, in this case 
for hepatotoxicity. 
All this discussion refers to plant products. However, 
if correctly applied, it could be extended to the analysis of 
other types of product.
It is extremely important to consider that safety 
assessment of nutritional products and supplements, 
plant-based or otherwise, should follow general guidelines 
for risk assessment of chemical substances in general, in 
which the following stages must be judiciously evaluated: 
hazard identification, hazard characterization, exposure 
assessment and risk characterization (EC, 2003; IPCS, 
1994; 1999; 2000; 2004; 2010). It should be noted that for 
these nutritional products, the history of use may provide 
valuable safety indications, and should be considered an 
essential tool in the safety assessment of these products. 
Thus, apart from knowledge of possible adverse events 
associated with chemical substances, it is important to 
detail the conditions of exposure to the products under 
assessment for a full understanding of the risks associated 
with consumption.
CONCLUSION
The demand for nutritional foods that can also 
yield health benefits has recently grown. In this group, 
products of plant origin have been particularly sought 
by the population, especially because of the historical 
misconception: natural is safe. In this context, is easy to tap 
an extensive market for natural products aimed at weight 
loss and popular healthy diet. Herbalife is a leading brand 
in this market, with a huge range of nutritional products 
and a substantial consumer base. Consequently, case 
reports involving its formulations and the possible health 
effects for users have been questioned.
It is important to bear in mind that the food 
supplements sector is regulated and supervised in 
most countries. Regulated products must follow Good 
Manufacturing Practices to ensure their homogeneity and 
quality, crucial points for risk evaluation and consumer 
safety. On the other hand, the association of adverse health 
effects with products from this sector has been a constant 
in the medical and ordinary literature. The same is true 
for disseminating their benefits, which often cannot be 
proved. Assigning an association to events is different 
from assigning causality. To assign causality, scientific 
and methodological rigor must be employed, which 
means that information must be complete, understandable 
and reliable. Moreover, the association of health risks or 
benefits with habits and behaviour is a daily practice, more 
related with risk perception than scientific proof.
In this article, the critical analysis of the publications 
available in the medical literature did not allow the 
attribution of causality between Herbalife product 
consumption and liver damage. Furthermore, the 
association between hepatotoxicity and consumption of 
these products cannot be proven based on data collected 
and rigorous scientific analysis. The technical-scientific 
limitation of the published papers associated with the non-
exclusion of competing diagnoses and the methodological 
limitation of the retrospective studies greatly weakens the 
causality relation. In addition to these facts, the lack of 
clear information on the type of products evaluated and 
their composition is an important factor to be considered. 
The majority of the authors of the publications 
evaluated in this review did not consistently characterize 
the product(s) involved. In several cases only the botanical 
origin of the products analysed was considered, clearly 
an erroneous approach. In addition, the components of 
the formulations, different exposed populations and the 
absence of effects in the majority of the consumers were 
not evaluated. Besides, the information collected and 
described in the literature does not allow speculation about 
the existence of sensitization in part of the population, 
a factor potentially involved with hepatotoxicity. The 
limitations of these studies and the importance of the 
clinical cases reported clearly demonstrate the need to 
include these products in health surveillance systems, with 
continuous nutravigilance monitoring (Schmitz, Lopez, 
Mackay, 2014).
Finally, in the safety assessment of food supplements 
and nutritional products, as important as it is to understand 
the potential adverse health effects (toxicity), it is critical 
to recognize the conditions to which the population is 
exposed, including the form of product presentation, its 
nutritional and chemical composition, purpose, proper 
use recommendations and target audience. Quantifying 
the potential exposure of the consumers to the formula 
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components, through diet or otherwise, is essential for 
proper estimation of the health risks. The correct and 
rational use of the supplements and dietetic formulations 
can contribute to promoting health and could yield benefits 
for users. However, the critical and scientific evaluation 
of risks and benefits is necessary to guarantee the health 
and welfare of the population.
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